VivoSeq
Cardiovascular

Catecholaminergic Polymorphic Ventricular Tachycardia

6

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Catecholaminergic Polymorphic Ventricular Tachycardia is an early-stage landscape with 6 programs across 6 companies. The most active players are Solid Biosciences Inc., Cardurion Pharmaceuticals, Inc., Agiana Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

15/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Solid Biosciences Inc.

1 program

Phase 1C

Cardurion Pharmaceuticals, Inc.

1 program

Phase 2A

Agiana Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

PreclinicalE

Eastern Cooperative Oncology Group

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Completed2 · 33%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Recruiting·AAgiana Pharmaceuticals·Phase 2·NCT07263139·10 enrolled
A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Recruiting·CCardurion Pharmaceuticals, Inc.·Phase 2·NCT06658899·12 enrolled
A Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Recruiting·SSolid Biosciences Inc.·Phase 1·NCT07148089·18 enrolled
Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Completed·VVanderbilt University·N/A·NCT02927223·6 enrolled
Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Completed·VVanderbilt University Medical Center·N/A·NCT01117454·14 enrolled
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Terminated·CCardurion Pharmaceuticals, Inc.·Phase 2·NCT06005428·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)